Did you mean: Grenier v. Wyeth, et al ?
Web Results

www.wlf.org/litigating/case_detail.asp?id=630

On February 22, 2011, the U. S. Supreme Court held that a federal law expressly preempts all state-law products liability suits challenging the design of widely ...

www.faegrebd.com/en/insights/publications/2011/2/supreme-court-decides-bruesewitz-v-wyeth-llc

Feb 22, 2011 ... On February 22, 2011, the U.S. Supreme Court decided Bruesewitz v. Wyeth LLC , No. 09-152, holding that the National Childhood Vaccine ...

www.americanbar.org/newsletter/publications/aba_health_esource_home/aba_health_law_esource_1104_brown.html

Bruesewitz v. Wyeth's Impact on the Vaccine Safety Debate. By Erin C. Fuse Brown1 & Jalayne J. Arias2, Public Health Law and Policy Program at Sandra Day ...

www.nejm.org/doi/pdf/10.1056/NEJMra0906357

Apr 22, 2010 ... sialic acid in all invasive meningococcal groups other than ..... er-membrane vesicle.52 Furthermore, Wyeth in- ..... Nedelec J, Boucraut J, Garnier JM, Ber- .... Bernfield L, Barniak V, et. 48. al. Vaccine potential of the Neisseria.

www.bloodjournal.org/content/102/3/949

Claude Granier .... All selected peptides had a higher-than-expected frequency of positive residues .... Indeed, anti-C2 Abs from different patients are mostly encoded by the DP-5 V gene, which is the case for Bo2C11. ... Supported by a grant from Wyeth Genetics Institute. ... Jacquemin MG, Desqueper BG, Benhida A , et al.

academic.oup.com/jcem/article/93/6/2097/2598323

Jun 1, 2008 ... In contrast, compared with controls, 2-h glucose (135 ± 23 vs.120 ± 25 mg/dl; P = 0.01) and fasting ...... Consistent with our findings, Sheu et al.

www.inta.org/TMR/Documents/Volume%20100/Vol100_no2_a1.pdf

Denise Garnier. González-Uribe .... Fabián Pablo Salvador Pelleriti et al. v. Instituto ...... The U.S. pharmaceutical company Wyeth is the owner of the trademark ...

aac.asm.org/content/47/9/2922.full

Fifteen years later, Fournier et al. ... However, through different molecular studies, Brisse et al. ... alone or combined with 4 μg of tazobactam (Wyeth-Lederle)/ml; cephalothin (Lilly, ..... Granier, S. A., V. Leflon-Guibout, F. W. Goldstein, and M. H.  ...

onlinelibrary.wiley.com/doi/full/10.1002/cncr.21326

Aug 22, 2005 ... Gemtuzumab ozogamicin (GO) (Mylotarg®; Wyeth Pharmaceuticals, Philadelphia , PA) is a ... At study entry, all patients had CD33‐positive AML in untreated first recurrence, .... CRp group, and 4.2 months for patients who did not enter remission (CR or CRp vs. ..... 6 Thomas X, Fenaux P, Dombret H, et al.